ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.874,53
-0,10%
S&P 500
5.746,16
0,01%
US Dollar vs BRL
5,43635
-0,03%
Bitcoin
65.920,27
1,13%
Brent Oil
71,145
0,27%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Castle Biosciences Inc (CSTL)

  7. Castle Biosciences Inc (CSTL) Notícias

CSTL

Castle Biosciences (CSTL)

Castle Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CSTL
DataHoraFonteTítuloCódigoCompanhia
23/09/202408:00Business WireNew Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s EsophagusNASDAQ:CSTLCastle Biosciences Inc
16/09/202408:00Business WireCastle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the YearNASDAQ:CSTLCastle Biosciences Inc
11/09/202408:00Business WireDecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study AffirmsNASDAQ:CSTLCastle Biosciences Inc
05/09/202417:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
05/09/202408:00Business WireStudy Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell CarcinomaNASDAQ:CSTLCastle Biosciences Inc
28/08/202408:00Business WireCastle Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:CSTLCastle Biosciences Inc
05/08/202417:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CSTLCastle Biosciences Inc
05/08/202417:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CSTLCastle Biosciences Inc
05/08/202417:05Business WireCastle Biosciences Reports Second Quarter 2024 ResultsNASDAQ:CSTLCastle Biosciences Inc
02/08/202416:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CSTLCastle Biosciences Inc
30/07/202408:00Business WireCastle Biosciences to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:CSTLCastle Biosciences Inc
22/07/202408:00Business WireCastle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of MelanomaNASDAQ:CSTLCastle Biosciences Inc
15/07/202408:00Business WireCastle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024NASDAQ:CSTLCastle Biosciences Inc
11/07/202408:00Business WireCastle Biosciences Honored with Top Workplaces AwardsNASDAQ:CSTLCastle Biosciences Inc
24/06/202408:00Business WireRecent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® TestNASDAQ:CSTLCastle Biosciences Inc
20/06/202408:00Business WireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CSTLCastle Biosciences Inc
14/06/202417:30Business WireCastle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award WinnerNASDAQ:CSTLCastle Biosciences Inc
30/05/202417:30Business WireCastle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging SurveillanceNASDAQ:CSTLCastle Biosciences Inc
29/05/202417:30Business WireNew Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of MetastasisNASDAQ:CSTLCastle Biosciences Inc
15/05/202408:00Business WireCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads ConferenceNASDAQ:CSTLCastle Biosciences Inc
14/05/202408:00Business WireCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024NASDAQ:CSTLCastle Biosciences Inc
10/05/202416:14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CSTLCastle Biosciences Inc
10/05/202408:00Business WireCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”NASDAQ:CSTLCastle Biosciences Inc
08/05/202417:30Business WireLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultNASDAQ:CSTLCastle Biosciences Inc
03/05/202408:00Business WireDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckNASDAQ:CSTLCastle Biosciences Inc
02/05/202417:05Business WireCastle Biosciences Reports First Quarter 2024 ResultsNASDAQ:CSTLCastle Biosciences Inc
30/04/202417:30Business WireCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaNASDAQ:CSTLCastle Biosciences Inc
11/04/202408:00Business WireCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024NASDAQ:CSTLCastle Biosciences Inc
10/04/202418:00Business WireCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsNASDAQ:CSTLCastle Biosciences Inc
10/04/202408:00Business WireCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CSTL

Seu Histórico Recente

TSXV
LIO
Lion One Metals
BIT
ADA113
Amagis Dynamic Alloc Tot...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados